Head-to-head evidence
albuterol / budesonide vs albuterol HFA (Armstrong's)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol / budesonide · Airsupra
Marketed by AstraZeneca
NCT03769090 · Phase 3 · completed
Participants were randomized and quadruple-blinded across two budesonide/albuterol groups and an active albuterol comparator, with 3,132 randomized participants. The primary clinical endpoint was met for both doses: severe exacerbations occurred in 207/1,013 versus 266/1,014 participants for high-dose treatment (hazard ratio 0.733, p<0.001) and 241/1,054 versus 276/1,056 for low-dose treatment (hazard ratio 0.835, p=0.041).
Next expected readout: February 2027 · NCT06422689 (registry estimate)
albuterol HFA (Armstrong's)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00635505 · Phase 3 · terminated
This is a randomized, quadruple-blind, placebo- and active-controlled study with an adequate sample size measuring lung function directly, but no results have been posted yet, so the outcome is unknown.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol / budesonide's landscape · albuterol HFA (Armstrong's)'s landscape